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Background:  Most patients with coronary disease present at least one classical cardiovascular risk factor (CRF) (dyslipidemia, hypertension, 
diabetes or smoking). Abnormalities of mineral metabolism have been related to cardiovascular damage
methods:  In 704 patients with coronary disease and age ≤85 years, we have studied plasma levels of biomarkers related to mineral metabolism 
[calcidiol (a vitamin D metabolite), fibroblast growth factor-23 (FGF-23), parathormone, and phosphate], inflammation [high-sensitivity C reactive 
protein (hsCRP), and monocyte chemoattractant protein-1 (MCP-1)], and heart failure [N-terminal pro brain natriuretic peptide (proBNP), and 
galectin 3]. We compared data from non-CRF with CRF cases. At follow-up, the development of the primary outcome (any acute coronary event, 
stroke, transient ischemic attack, heart failure or death) was assessed in both groups.
results:  Twenty patients (2.8%) had not CRF. They had lower glucose, and triglyceride levels, higher HDL levels, and used less often oral 
antidiabetic drugs than CRF cases. Age (63.5±11.9 vs 61.4±12.3 years; p=0.45) and the remaining clinical data were similar, including sex, ejection 
fraction, glomerular filtration rate, and drug therapy. They had lower levels of hsCRP [1.29 (0.94-2.56) vs 2.02 (0.83-4.13) pg/ml; p=0.017], MCP-1 
[103.6 (89.3-129.3) vs 131.6 (105.0-167.3) pg/ml; p=0.002] and FGF-23 [64.25 (49.08-96.72) vs 70.05 (55.08-96.21) RU/ml; p=0.024] and 
higher calcidiol levels (23.66±9.12 vs 19.49±8.18 ng/ml; p=0.025) without differences in proBNP, galectin-3, parathormone and phosphate levels. 
At follow-up [2.12 (1.37-2.98) years], 10.9% cases in the non-CRF group and 11.0% in the CRF group developed the outcome (p=0.816, log-rank 
test). To avoid a potential bias due to different group sizes, we repeated all the analyses comparing non-CRF cases with 40 CRF cases matched for 
age and gender, obtaining similar results.
conclusions:  A small group of patients with coronary artery disease do not present CRF. They show a more favourable biomarker profile than those 
with CFR. Although the prognosis was similar in both groups, this finding could be limited by the low sample size of the non-CRF group.
